Neuropsychopharmacology

3Z: Zebrafish mutant model reveals novel drug candidates for ADHD

Retrieved on: 
Tuesday, November 22, 2022

In a study published in the journal Neuropsychopharmacology, 3Z scientists and collaborators used a uniquely powerful genetic model and unbiased drug screen to identify novel ADHD non-stimulant therapeutics.

Key Points: 
  • In a study published in the journal Neuropsychopharmacology, 3Z scientists and collaborators used a uniquely powerful genetic model and unbiased drug screen to identify novel ADHD non-stimulant therapeutics.
  • First, it was shown that when the human ADHD risk gene Latrophilin 3 was knocked-out in zebrafish, they showed a robust hyperactive behavior, consistent with ADHD.
  • In summary, 3Z introduced a genetic model of ADHD in zebrafish and identified five novel putative therapeutics.
  • The findings offer a novel tool for understanding ADHD, suggest a novel mechanism for its etiology and identify novel candidate therapeutics.

3Z: Zebrafish mutant model reveals novel drug candidates for ADHD

Retrieved on: 
Tuesday, November 22, 2022

In a study published in the journal Neuropsychopharmacology, 3Z scientists and collaborators used a uniquely powerful genetic model and unbiased drug screen to identify novel ADHD non-stimulant therapeutics.

Key Points: 
  • In a study published in the journal Neuropsychopharmacology, 3Z scientists and collaborators used a uniquely powerful genetic model and unbiased drug screen to identify novel ADHD non-stimulant therapeutics.
  • First, it was shown that when the human ADHD risk gene Latrophilin 3 was knocked-out in zebrafish, they showed a robust hyperactive behavior, consistent with ADHD.
  • In summary, 3Z introduced a genetic model of ADHD in zebrafish and identified five novel putative therapeutics.
  • The findings offer a novel tool for understanding ADHD, suggest a novel mechanism for its etiology and identify novel candidate therapeutics.

Clinical Director of Imperial College's Center for Psychedelic Research Joins Entheon Advisory Board

Retrieved on: 
Wednesday, August 25, 2021

Dr. David Erritzoe to provide guidance on psychopharmacological research

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - August 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that Dr. David Erritzoe, the current Clinical Director of the Imperial College's Center for Psychedelic Research, has been appointed to Entheon's Advisory Board.
  • Dr. Erritzoe has significant experience in psychiatry, neuropsychopharmacology and psychedelic research.
  • He is currently leading a new National Health Service (BHS) based research clinic, the CIPPRes Clinic, a collaborative, multidisciplinary research initiative between the Imperial College in London and the St. Charles Hospital.
  • Dr. Erritzoe conducts research using brain imaging techniques including PET and MRI scans and has conducted research into the neurobiology of addictions and depression.

Awakn Acquires Proprietary Next Generation MDMA and Ketamine Data from Prof. David Nutt

Retrieved on: 
Tuesday, March 9, 2021

Prof. Nutt appointed Head of Research to Lead Awakn's Next-Gen Psychedelic Molecule Development

Key Points: 
  • In addition to the acquisition of the data, Prof. Nutt has been appointed as Head of Research to lead Awakn's next generation psychedelic molecule development programme.
  • Anthony Tennyson, CEO Awakn Life Sciences, commented, "This is another great step forward for Awakn.
  • David John Nutt is an English neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep.
  • Nutt was a member of the Committee on Safety of Medicines and was President of the European College of Neuropsychopharmacology.

Cohen Veterans Bioscience And The European College Of Neuropsychopharmacology Announce The 2021 Best Negative Data Prize In Clinical Neuroscience

Retrieved on: 
Monday, March 8, 2021

NEW YORK, March 8, 2021 /PRNewswire/ --Cohen Veterans Bioscience (CVB) and the European College of Neuropsychopharmacology (ECNP) are pleased to announce the opening of submissions for the 2021 Best Negative Data Prize in Clinical Neuroscience.

Key Points: 
  • NEW YORK, March 8, 2021 /PRNewswire/ --Cohen Veterans Bioscience (CVB) and the European College of Neuropsychopharmacology (ECNP) are pleased to announce the opening of submissions for the 2021 Best Negative Data Prize in Clinical Neuroscience.
  • The prize recognizes the researcher or research group whose publication in clinical neuroscience best exemplifies clinical data where the results do not confirm the expected outcomes or original hypotheses or results that challenge a long-standing clinical precedent.
  • CVB's sponsorship of the 2021 prize for clinical neuroscience extends the organization's previous sponsorship of the same prize for preclinical neuroscience, which has been awarded biannually since 2018.
  • The call for submissions for the 2021 Best Negative Data Prize in Clinical Neuroscience will open on March 8, 2021, with a closing date of April 30th, 2021.

Global Preclinical Data Forum and European College of Neuropsychopharmacology Announce the Winner of the 2020 Best Negative Data Prize

Retrieved on: 
Monday, September 14, 2020

NEW YORK, Sept. 14, 2020 /PRNewswire/ --The Global Preclinical Data Forum (GPDF; https://www.preclinicaldataforum.org/ ), ajointly sponsored U.S. and European initiative, funded by Cohen Veterans Bioscience (CVB) and the European College of Neuropsychopharmacology (ECNP), announced today the winner of the 2020 "Best Negative Data Prize."

Key Points: 
  • NEW YORK, Sept. 14, 2020 /PRNewswire/ --The Global Preclinical Data Forum (GPDF; https://www.preclinicaldataforum.org/ ), ajointly sponsored U.S. and European initiative, funded by Cohen Veterans Bioscience (CVB) and the European College of Neuropsychopharmacology (ECNP), announced today the winner of the 2020 "Best Negative Data Prize."
  • "I've always advocated for publishing negative results and many of myexperimental papers reveal full or partially failed replication attempts.
  • The Best Negative Data Prize aims to initiate a paradigm shift in which negative data is valued according to the same standards as positive data.
  • The European College of Neuropsychopharmacology (ECNP) is an independent scientific association dedicated to the science and treatment of disorders of the brain.

Global Preclinical Data Forum Announces 2020 Negative Prize Award

Retrieved on: 
Tuesday, April 7, 2020

NEW YORK, April 7, 2020 /PRNewswire/ -- The Global Preclinical Data Forum (GPDF), a partnership of Cohen Veterans Bioscience (CVB), a non-profit research biotech, and the European College of Neuropsychopharmacology (ECNP), is pleased to announce the opening of submissions for the 2020 Best Negative Data Prize competition.

Key Points: 
  • NEW YORK, April 7, 2020 /PRNewswire/ -- The Global Preclinical Data Forum (GPDF), a partnership of Cohen Veterans Bioscience (CVB), a non-profit research biotech, and the European College of Neuropsychopharmacology (ECNP), is pleased to announce the opening of submissions for the 2020 Best Negative Data Prize competition.
  • This prize, which was first launched in 2017, will award 10,000 to the researcher/research group whose publication in neuroscience research best exemplifies data where the results do not confirm the expected outcomes or original hypotheses.
  • The Best Negative Data Prize provides an incentive for preclinical researchers of all fields to publish their "negative data" results and ensure that studies in neuroscience properly advance knowledge.
  • The GPDF opens a call for submissions for the Best Negative Data Prize in neuroscience beginning Tuesday, April 7, 2020 with a closing date on April 21, 2020.

Sunovion Announces Results from Its Open-Label Extension Study of SEP-363856 in Schizophrenia

Retrieved on: 
Thursday, December 12, 2019

Results of study SEP361-202, the open-label extension study of the four-week, double-blind, placebo-controlled study SEP361-201, were presented at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Orlando, Fla.

Key Points: 
  • Results of study SEP361-202, the open-label extension study of the four-week, double-blind, placebo-controlled study SEP361-201, were presented at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Orlando, Fla.
  • The study results were presented as a poster titled Safety and Effectiveness of SEP-363856 in Schizophrenia: Results of a 6-Month, Open-Label Extension Study, (Poster #W204).
  • We look forward to swiftly progressing our global Phase 3 clinical studies of SEP-363856 in both adult and adolescent patients with schizophrenia.
  • In addition to the SEP361-202 open-label extension data for SEP-363856, Sunovion presented two posters highlighting new data at ACNP 2019.

Cadent Therapeutics Announces Poster Presentation at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

Retrieved on: 
Tuesday, December 10, 2019

The poster will be presented on Tuesday, December 10, 2019, from 5:30 PM to 7:30 PM at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP) taking place December 8-11 in Orlando, Florida.

Key Points: 
  • The poster will be presented on Tuesday, December 10, 2019, from 5:30 PM to 7:30 PM at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP) taking place December 8-11 in Orlando, Florida.
  • Cadent Therapeutics is creating therapies for the treatment of movement, mood, and cognitive disorders.
  • Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric modulators to treat spinocerebellar ataxia, essential tremor, and schizophrenia.
  • Investors include Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners, Access Industries, Clal Biotechnology Industries, Novartis Corporate and Slater Technology Fund.

Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

Retrieved on: 
Tuesday, December 10, 2019

The planned progression of SAGE-718 is based on results from Phase 1 studies evaluating the safety and tolerability of SAGE-718, including an open-label cohort of patients with HD.

Key Points: 
  • The planned progression of SAGE-718 is based on results from Phase 1 studies evaluating the safety and tolerability of SAGE-718, including an open-label cohort of patients with HD.
  • In the study, SAGE-718 was well tolerated, with no serious adverse events or adverse events leading to treatment discontinuation.
  • These results are comparable to improvements in measures of executive function observed in an earlier Phase 1 cohort of individuals without HD.
  • In addition, the Company is presenting data from three other non-clinical and Phase 1 studies with SAGE-718 at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP).